People with Premenstrual Dysphoric Disorder Have Higher Rates of Suicidal Thinking, Planning and Attempts

Why It Matters

Elevated suicide risk makes early identification and treatment of PMDD a public‑health priority, prompting clinicians to screen for suicidality in this population.

Key Takeaways

• Review of 18 studies links PMDD to higher suicide risk
• Suicidal thoughts reported by ~33% of adolescents with PMDD
• Adult PMDD sufferers show ~25% suicidal ideation or planning
• Prevalence varies widely, highlighting methodological differences across studies

Pulse Analysis

PMDD, recognized in 2013, is a severe, chronic form of premenstrual syndrome that affects up to 6 % of people who menstruate. Unlike typical PMS, PMDD produces debilitating mood swings, irritability, and depressive symptoms that persist across menstrual cycles. Diagnosis requires prospective symptom tracking over at least two cycles, a process that can delay care for many patients. The disorder’s impact extends beyond personal distress, influencing work productivity, relationships, and overall quality of life, making it a significant yet often under‑recognized public‑health issue.

A new systematic review examined 18 studies encompassing more than two million menstruating individuals and found a striking association between PMDD and suicidality. Reported rates of suicidal thoughts, plans, or attempts ranged from a low of 0.011 % in large population samples to as high as 86 % in tightly defined clinical cohorts. Adolescents with PMDD exhibited roughly one‑third prevalence, while adult women reported about a quarter. This variability reflects differences in study design, diagnostic criteria, and timing of assessment within the hormonal cycle, underscoring the need for standardized measurement.

Although no trials have tested interventions specifically for suicide risk in PMDD, evidence‑based treatments—selective serotonin reuptake inhibitors, hormonal contraceptives, hormone‑blocking agents, cognitive‑behavioral therapy, and lifestyle modifications—can alleviate core symptoms and may indirectly reduce suicidal ideation. Clinicians should incorporate routine suicide screening when evaluating patients with PMDD and coordinate care with mental‑health specialists. Further research is required to map how hormonal fluctuations modulate risk and to develop targeted prevention strategies. Recognizing PMDD as a driver of suicidality could reshape screening guidelines and improve outcomes for a vulnerable population.